Register Login
Register to leave comments
  • News bot Aug. 11, 2026, 8:06 p.m.

    📋 BOLT BIOTHERAPEUTICS, INC. (BOLT) - Financial Results

    Filing Date: 2026-08-11

    Accepted: 2026-08-11 16:05:15

    Event Type: Financial Results

    Event Details:

    BOLT BIOTHERAPEUTICS, INC. (BOLT) Reports the reporting period Financial Results BOLT BIOTHERAPEUTICS, INC. (BOLT) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 717
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 14598
      • anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.Investor Relations and Media Contact: Matthew DeYoung Argot Partners (212) 600-1902
      • targeting claudin 18.2. BDC-4182
      • targeting CEA and PD-L1. For more information, please visit https://www.boltbio.com/.Forward-Looking StatementsThis press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our ability to partner our CEA ISAC and PD-L1 ISAC, the advancement and success of our BDC-4182

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 9.21K 15.97K $-6.76K -42.35%
    Other Income Expense Net Other Income Net 50.00 557.00 $-507.00 -91.02%
    Other Income Expense Net Total Other Income Expense 649.00 1.01K $-362.00 -35.81%
    Other Income Expense Net Net Loss 8.56K 14.96K $-6.40K -42.79%
    Other Income Expense Net Net Loss Per Share 4.46 8.88 $-4.42 -49.77%
    Current Assets Prepaid Expenses Other Current Assets 2.77K 2.56K $211.00 +8.26%
    Current Assets Property Equipment Net 571.00 1.25K $-674.00 -54.14%
    Current Assets Operating Lease Right Of Use Assets 17.07K 19.23K $-2.15K -11.21%
    Current Assets Other Assets 87.00 138.00 $-51.00 -36.96%
    Current Liabilities Accounts Payable 868.00 1.44K $-575.00 -39.85%
    Current Liabilities Operating Lease Liabilities 3.09K 2.83K $265.00 +9.38%
    Current Liabilities Other Long Term Liabilities 132.00 132.00 $0.00 +0.00%
    Cash Flows From Operating Activities Net Loss 14.96K 19.60K $-4.64K -23.66%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 160.00 236.00 $-76.00 -32.20%
    Changes In Operating Assets And Liabilities Operating Lease Liabilities 1.33K 1.03K $308.00 +30.02%
    Revenue 5.00 1.80K $-1.80K -99.72%
    Loss from Operations 8.37K 9.21K $-836.00 -9.08%
    Interest Income 178.00 599.00 $-421.00 -70.28%
    Other Income, Net 476.00 50.00 $426.00 +852.00%
    Total Other Income/(Expense) 654.00 649.00 $5.00 +0.77%
    Net Loss 7.72K 8.56K $-841.00 -9.82%
    Prepaid Expenses and Other Current Assets 2.77K 2.56K $211.00 +8.26%
    Property and Equipment, Net 571.00 1.25K $-674.00 -54.14%
    Other Assets 87.00 138.00 $-51.00 -36.96%
    Accounts Payable 868.00 1.44K $-575.00 -39.85%
    Operating Lease Liabilities 3.09K 2.83K $265.00 +9.38%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BOLT BIOTHERAPEUTICS, INC.
    • Ticker Symbol: BOLT

Search

News categories